Experimental models to study lymphatic and blood vascular metastasis

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 475-483

  Chen, Lu ^a   Hann, Byron ^b   Wu, Lily ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cornea; lymph node; lymphangiogenesis; lymphatic pathway; metastasis; PET, luciferase

Indexed keywords

ARTICLE; CANCER CELL; CORNEA TRANSPLANTATION; GENE EXPRESSION; HUMAN; INFLAMMATION; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; METASTASIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; CORNEA; DISEASE MODELS, ANIMAL; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MICE; MOLECULAR IMAGING; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS;

EID: 79953884624     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21794     Document Type: Article

References (96)

1. Chen L,: Ocular lymphatics: State-of-the-art review. Lymphology 2009; 42: 66-76.
2. Alitalo K, Tammela T, Petrova TV,: Lymphangiogenesis in development and human disease. Nature 2005; 438: 946-953. (Pubitemid 43093960)
3. Brown P,: Lymphatic system: Unlocking the drains. Nature 2005; 436: 456-458. (Pubitemid 41112892)
4. Jackson DG,: The lymphatics revisited: New perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med 2003; 13: 1-7. (Pubitemid 36120543)
5. Chang L, Kaipainen A, Folkman J,: Lymphangiogenesis new mechanisms. Ann N Y Acad Sci 2002; 979: 111-119.
6. Folkman J, Kaipainen A,: Genes tell lymphatics to sprout or not. Nat Immunol 2004; 5: 11-12. (Pubitemid 38081460)
7. Oliver G, Detmar M,: The rediscovery of the lymphatic system: Old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 2002; 16: 773-783. (Pubitemid 34280101)
8. Collin HB,: Endothelial cell lined lymphatics in the vascularized rabbit cornea. Invest Ophthalmol 1966; 5: 337-354.
9. Collin HB,: Ultrastructure of lymphatic vessels in the vascularized rabbit cornea. Exp Eye Res 1970; 10: 207-213.
10. Cursiefen C, Chen L, Dana MR, et al.: Corneal lymphangiogenesis: Evidence, mechanisms, and implications for corneal transplant immunology. Cornea 2003; 22: 273-281. (Pubitemid 36359171)
11. Chen L, Cursiefen C, Barabino S, et al.: Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Invest Ophthalmol Vis Sci 2005; 46: 4536-4540. (Pubitemid 44264550)
12. Cheng WS, Kraaij R, Nilsson B, et al.: A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol Ther 2004; 10: 355-364. (Pubitemid 39117880)
13. Chen L, Hamrah P, Cursiefen C, et al.: Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004; 10: 813-815. (Pubitemid 39070853)
14. Cursiefen C, Chen L, Borges LP, et al.: VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113: 1040-1050. (Pubitemid 38544126)
15. Ecoiffier TYD, Chen L,: Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Ophthalmol Vis Sci 2010; 51: 2436-2440.
16. Folkman J,: Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
17. Gimbrone MA, Jr., Cotran RS, Leapman SB, et al.: Tumor growth and neovascularization: An experimental model using the rabbit cornea. J Natl Cancer Inst 1974; 52: 413-427.
18. Chang LK, Garcia-Cardena G, Farnebo F, et al.: Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci USA 2004; 101: 11658-11663. (Pubitemid 39095352)
19. Ziche M, Morbidelli L,: The corneal pocket assay. Methods Mol Biol 2009; 467: 319-329.
20. Bjorndahl M, Cao R, Nissen LJ, et al.: Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 15593-15598. (Pubitemid 41528101)
21. Langer R, Folkman J,: Polymers for the sustained release of proteins and other macromolecules. Nature 1976; 263: 797-800.
22. Loughman MS, Chatzistefanou K, Gonzalez EM, et al.: Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor. Aust N Z J Ophthalmol 1996; 24: 289-295. (Pubitemid 26405309)
23. Rogers MS, Birsner AE, D'Amato RJ,: The mouse cornea micropocket angiogenesis assay. Nat Protoc 2007; 2: 2545-2550.
24. Junghans BM, Collin HB,: Limbal lymphangiogenesis after corneal injury: An autoradiographic study. Curr Eye Res 1989; 8: 91-100. (Pubitemid 19073793)
25. Ling S, Lin H, Liang L, et al.: Development of new lymphatic vessels in alkali-burned corneas. Acta Ophthalmol 2009; 87: 315-322.
26. Albuquerque RJ, Hayashi T, Cho WG, et al.: Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009; 15: 1023-1030.
27. Chen L, Huq S, Gardner H, et al.: Very late antigen 1 blockade markedly promotes survival of corneal allografts. Arch Ophthalmol 2007; 125: 783-788. (Pubitemid 46919739)
28. Cursiefen C, Ikeda S, Nishina PM, et al.: Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am J Pathol 2005; 166: 1367-1377. (Pubitemid 40586508)
29. Liu Y, Hamrah P, Zhang Q, et al.: Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med 2002; 195: 259-268. (Pubitemid 34461269)
30. Yamagami S, Dana MR,: The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci 2001; 42: 1293-1298. (Pubitemid 32381972)
31. Achen MG, McColl BK, Stacker SA,: Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005; 7: 121-127. (Pubitemid 40248338)
32. Tammela T, Alitalo K,: Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010; 140: 460-476.
33. Harisinghani MG, Barentsz J, Hahn PF, et al.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-2499. (Pubitemid 36706536)
34. Christofk HR, Vander Heiden MG, Harris MH, et al.: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233. (Pubitemid 351380249)
35. Flier JS, Mueckler MM, Usher P, et al.: Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235: 1492-1495. (Pubitemid 17038084)
36. Beyer T, Townsend DW, Brun T, et al.: A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379. (Pubitemid 30643379)
37. Liu IJ, Zafar MB, Lai YH, et al.: Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57: 108-111. (Pubitemid 32065829)
38. Shreve PD, Grossman HB, Gross MD, et al.: Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro- D -glucose. Radiology 1996; 199: 751-756.
39. Seltzer MA, Barbaric Z, Belldegrun A, et al.: Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162: 1322-1328. (Pubitemid 29428572)
40. Larson SM, Morris M, Gunther I, et al.: Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004; 45: 366-373. (Pubitemid 47618608)
41. Chen Y, Sawyers CL, Scher HI,: Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8: 440-448.
42. DeGrado TR, Coleman RE, Wang S, et al.: Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 2001; 61: 110-117. (Pubitemid 32095708)
43. Schuster DM, Votaw JR, Nieh PT, et al.: Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48: 56-63. (Pubitemid 47555376)
44. Picchio M, Messa C, Landoni C, et al.: Value of [11C]choline-positron emission tomography for re-staging prostate cancer: A comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169: 1337-1340. (Pubitemid 36323779)
45. Yamaguchi T, Lee J, Uemura H, et al.: Prostate cancer: A comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005; 32: 742-748. (Pubitemid 41125415)
46. Scattoni V, Picchio M, Suardi N, et al.: Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: Results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52: 423-429. (Pubitemid 46963456)
47. Rinnab L, Mottaghy FM, Simon J, et al.: [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 2008; 81: 191-197.
48. Shu X, Royant A, Lin MZ, et al.: Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science 2009; 324: 804-807.
49. Gambhir SS, Bauer E, Black ME, et al.: A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 2000; 97: 2785-2790. (Pubitemid 30159249)
50. Groot-Wassink T, Aboagye EO, Glaser M, et al.: Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 2002; 13: 1723-1735. (Pubitemid 35191747)
51. Rogers BE, Chaudhuri TR, Reynolds PN, et al.: Non-invasive gamma camera imaging of gene transfer using an adenoviral vector encoding an epitope-tagged receptor as a reporter. Gene Ther 2003; 10: 105-114. (Pubitemid 36582582)
52. Massoud TF, Gambhir SS,: Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-580. (Pubitemid 36307540)
53. Singh A, Massoud TF, Deroose C, et al.: Molecular imaging of reporter gene expression in prostate cancer: An overview. Semin Nucl Med 2008; 38: 9-19. (Pubitemid 350256714)
54. Kang JH, Chung JK,: Molecular-genetic imaging based on reporter gene expression. J Nucl Med 2008; 49: 164S-179S.
55. Gambhir SS,: Molecular imaging with reporter genes. Cambridge: Cambridge University Press; 2010.
56. Figueiredo ML, Kao C, Wu L,: Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther 2007; 15: 1053-1064. (Pubitemid 46813607)
57. Adams JY, Johnson M, Sato M, et al.: Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 2002; 8: 891-897.
58. Latham JP, Searle PF, Mautner V, et al.: Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334-341. (Pubitemid 30070760)
59. Yu DC, Sakamoto GT, Henderson DR,: Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999; 59: 1498-1504. (Pubitemid 29160117)
60. Zhang Y, Yu J, Unni E, et al.: Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. Hum Gene Ther 2002; 13: 2051-2064. (Pubitemid 35417350)
61. Lee SJ, Zhang Y, Lee SD, et al.: Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther 2004; 10: 1051-1058. (Pubitemid 39625249)
62. Iyer M, Wu L, Carey M, et al.: Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA 2001; 98: 14595-14600. (Pubitemid 33121437)
63. Zhang L, Adams JY, Billick E, et al.: Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther 2002; 5: 223-232. (Pubitemid 34211217)
64. Sato M, Johnson M, Zhang L, et al.: Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res 2005; 11: 3743-3749. (Pubitemid 40685591)
65. Johnson M, Sato M, Burton J, et al.: Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: The advantage of a cell-specific transcriptional targeting approach. Mol Imaging 2005; 4: 463-472. (Pubitemid 43143786)
66. Ray S, Paulmurugan R, Patel MR, et al.: Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol Ther 2008; 16: 1848-1856.
67. Huyn ST, Burton JB, Sato M, et al.: A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis. Clin Cancer Res 2009; 15: 3126-3134.
68. Chen IY, Gheysens O, Ray S, et al.: Indirect imaging of cardiac-specific transgene expression using a bidirectional two-step transcriptional amplification strategy. Gene Ther 2010; 17: 827-838.
69. Szuba A, Shin WS, Strauss HW, et al.: The third circulation: Radionuclide lymphoscintigraphy in the evaluation of lymphedema. J Nucl Med 2003; 44: 43-57. (Pubitemid 36077712)
70. Ikomi F, Hanna GK, Schmid-Schonbein GW,: Size- and surface-dependent uptake of colloid particles into the lymphatic system. Lymphology 1999; 32: 90-102. (Pubitemid 29427130)
71. Ikomi F, Hanna GK, Schmid-Schonbein GW,: Mechanism of colloidal particle uptake into the lymphatic system: Basic study with percutaneous lymphography. Radiology 1995; 196: 107-113.
72. Giuliano AE, Kirgan DM, Guenther JM, et al.: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391-398 discussion 8-401.
73. Gervasi LA, Mata J, Easley JD, et al.: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989; 142: 332-336. (Pubitemid 19197108)
74. Roehl KA, Han M, Ramos CG, et al.: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 2004; 172: 910-914. (Pubitemid 39096421)
75. Masterson TA, Bianco FJ, Jr., Vickers AJ, et al.: The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006; 175: 1320-1324; discussion 1324-1325.
76. Zeng Y, Opeskin K, Baldwin ME, et al.: Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004; 10: 5137-5144. (Pubitemid 39099788)
77. Jennbacken K, Vallbo C, Wang W, et al.: Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005; 65: 110-116. (Pubitemid 41362277)
78. Brakenhielm E, Burton JB, Johnson M, et al.: Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer 2007; 121: 2153-2161. (Pubitemid 47585593)
79. Burton JB, Priceman SJ, Sung JL, et al.: Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008; 68: 7828-7837.
80. Mattei A, Fuechsel FG, Bhatta Dhar N, et al.: The template of the primary lymphatic landing sites of the prostate should be revisited: Results of a multimodality mapping study. Eur Urol 2008; 53: 118-125. (Pubitemid 350166722)
81. Heidenreich A, Ohlmann CH, Polyakov S,: Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007; 52: 29-37. (Pubitemid 46803038)
82. Labow D, Lee S, Ginsberg RJ, et al.: Adenovirus vector-mediated gene transfer to regional lymph nodes. Hum Gene Ther 2000; 11: 759-769. (Pubitemid 30180280)
83. Johnson M, Huyn S, Burton J, et al.: Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther 2006; 17: 1262-1269. (Pubitemid 44975142)
84. Kishimoto H, Kojima T, Watanabe Y, et al.: In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 2006; 12: 1213-1219. (Pubitemid 44527360)
85. Burton JB, Johnson M, Sato M, et al.: Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med 2008; 14: 882-888.
86. Kishimoto H, Urata Y, Tanaka N, et al.: Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther 2009; 8: 3001-3008.
87. Sato M, Figueiredo ML, Burton JB, et al.: Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging. Gene Ther 2008; 15: 583-593.
88. Penuelas I, Mazzolini G, Boan JF, et al.: Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 2005; 128: 1787-1795. (Pubitemid 40824689)
89. Barton KN, Stricker H, Brown SL, et al.: Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 2008; 16: 1761-1769.
90. Liu H, Jin L, Koh SBS, et al.: Atomic structure of human adenovirus by cryoEM reveals networks of protein interactions. Science 2010; 329: 1038-1043.
91. Waddington SN, McVey JH, Bhella D, et al.: Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409. (Pubitemid 351200513)
92. Roberts DM, Nanda A, Havenga MJ, et al.: Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006; 441: 239-243.
93. Everts M, Curiel DT,: Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther 2004; 4: 337-346. (Pubitemid 39162394)
94. Ntziachristos V, Bremer C, Weissleder R,: Fluorescence imaging with near-infrared light: New technological advances that enable in vivo molecular imaging. Eur Radiol 2003; 13: 195-208. (Pubitemid 36790510)
95. Edinger M, Cao YA, Hornig YS, et al.: Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 2002; 38: 2128-2136. (Pubitemid 35223250)
96. MacLaren DC, Gambhir SS, Satyamurthy N, et al.: Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999; 6: 785-791. (Pubitemid 29243651)